190 related articles for article (PubMed ID: 36544142)
1. A combination of molecular and clinical parameters provides a new strategy for high-grade serous ovarian cancer patient management.
Bradbury M; Borràs E; Vilar M; Castellví J; Sánchez-Iglesias JL; Pérez-Benavente A; Gil-Moreno A; Santamaria A; Sabidó E
J Transl Med; 2022 Dec; 20(1):611. PubMed ID: 36544142
[TBL] [Abstract][Full Text] [Related]
2. Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma.
Tessier-Cloutier B; Cochrane DR; Karnezis AN; Colborne S; Magrill J; Talhouk A; Zhang J; Leung S; Hughes CS; Piskorz A; Cheng AS; Greening K; du Bois A; Pfisterer J; Soslow RA; Kommoss S; Brenton JD; Morin GB; Gilks CB; Huntsman DG; Kommoss F
Hum Pathol; 2020 Jul; 101():40-52. PubMed ID: 32360491
[TBL] [Abstract][Full Text] [Related]
3. Targeted Mass Spectrometry of Longitudinal Patient Sera Reveals LTBP1 as a Potential Surveillance Biomarker for High-Grade Serous Ovarian Carcinoma.
Wenk D; Khan S; Ignatchenko V; May T; Bernardini MQ; Kislinger T
J Proteome Res; 2024 Feb; 23(2):749-759. PubMed ID: 38266179
[TBL] [Abstract][Full Text] [Related]
4. Proteomics of High-Grade Serous Ovarian Cancer Models Identifies Cancer-Associated Fibroblast Markers Associated with Clinical Outcomes.
Govindarajan M; Ignatchenko V; Ailles L; Kislinger T
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671461
[TBL] [Abstract][Full Text] [Related]
5. Integrative prognostic subtype discovery in high-grade serous ovarian cancer.
Xie H; Xu H; Hou Y; Cai Y; Rong Z; Song W; Wang W; Li K
J Cell Biochem; 2019 Nov; 120(11):18659-18666. PubMed ID: 31347734
[TBL] [Abstract][Full Text] [Related]
6. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
[TBL] [Abstract][Full Text] [Related]
7. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
8. High-throughput approaches for precision medicine in high-grade serous ovarian cancer.
Govindarajan M; Wohlmuth C; Waas M; Bernardini MQ; Kislinger T
J Hematol Oncol; 2020 Oct; 13(1):134. PubMed ID: 33036656
[TBL] [Abstract][Full Text] [Related]
9. Single-cell RNA-sequencing analysis reveals divergent transcriptome events between platinum-sensitive and platinum-resistant high-grade serous ovarian carcinoma.
Wang Z; Yang L; Su X; Wu X; Su R
J Gene Med; 2023 Oct; 25(10):e3504. PubMed ID: 36994597
[TBL] [Abstract][Full Text] [Related]
10.
Valle BL; Rodriguez-Torres S; Kuhn E; Díaz-Montes T; Parrilla-Castellar E; Lawson FP; Folawiyo O; Ili-Gangas C; Brebi-Mieville P; Eshleman JR; Herman J; Shih IM; Sidransky D; Guerrero-Preston R
Cancer Prev Res (Phila); 2020 Sep; 13(9):783-794. PubMed ID: 32581010
[TBL] [Abstract][Full Text] [Related]
11. Proteomics-Derived Biomarker Panel Improves Diagnostic Precision to Classify Endometrioid and High-grade Serous Ovarian Carcinoma.
Dieters-Castator DZ; Rambau PF; Kelemen LE; Siegers GM; Lajoie GA; Postovit LM; Köbel M
Clin Cancer Res; 2019 Jul; 25(14):4309-4319. PubMed ID: 30979743
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian Cancer.
Lou E; Clemente V; Grube M; Svedbom A; Nelson AC; Blome F; Staebler A; Kommoss S; Bazzaro M
JAMA Netw Open; 2024 Feb; 7(2):e240407. PubMed ID: 38411963
[TBL] [Abstract][Full Text] [Related]
13. N-Glycoproteomics of Patient-Derived Xenografts: A Strategy to Discover Tumor-Associated Proteins in High-Grade Serous Ovarian Cancer.
Sinha A; Hussain A; Ignatchenko V; Ignatchenko A; Tang KH; Ho VWH; Neel BG; Clarke B; Bernardini MQ; Ailles L; Kislinger T
Cell Syst; 2019 Apr; 8(4):345-351.e4. PubMed ID: 30981729
[TBL] [Abstract][Full Text] [Related]
14. Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment.
Finkernagel F; Reinartz S; Schuldner M; Malz A; Jansen JM; Wagner U; Worzfeld T; Graumann J; von Strandmann EP; Müller R
Theranostics; 2019; 9(22):6601-6617. PubMed ID: 31588238
[TBL] [Abstract][Full Text] [Related]
15. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.
Santillan A; Kim YW; Zahurak ML; Gardner GJ; Giuntoli RL; Shih IM; Bristow RE
Int J Gynecol Cancer; 2007; 17(3):601-6. PubMed ID: 17504374
[TBL] [Abstract][Full Text] [Related]
16. Expression of serum human epididymal secretory protein E4 at low grade and high grade serous carcinomas.
Zhu YF; He LS; Zhang ZD; Huang QS
Asian Pac J Trop Med; 2012 Dec; 5(12):925-30. PubMed ID: 23199707
[TBL] [Abstract][Full Text] [Related]
17. ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy.
Nadaraja S; Schledermann D; Herrstedt J; Østrup O; Ditzel HJ;
Acta Oncol; 2020 Jan; 59(1):40-47. PubMed ID: 31478407
[No Abstract] [Full Text] [Related]
18. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
19. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.
Kang EY; Millstein J; Popovic G; Meagher NS; Bolithon A; Talhouk A; Chiu DS; Anglesio MS; Leung B; Tang K; Lambie N; Pavanello M; Da-Anoy A; Lambrechts D; Loverix L; Olbrecht S; Bisinotto C; Garcia-Donas J; Ruiz-Llorente S; Yagüe-Fernandez M; Edwards RP; Elishaev E; Olawaiye A; Taylor S; Ataseven B; du Bois A; Harter P; Lester J; Høgdall CK; Armasu SM; Huang Y; Vierkant RA; Wang C; Winham SJ; Heublein S; Kommoss FKF; Cramer DW; Sasamoto N; van-Wagensveld L; Lycke M; Mateoiu C; Joseph J; Pike MC; Odunsi K; Tseng CC; Pearce CL; Bilic S; Conrads TP; Hartmann A; Hein A; Jones ME; Leung Y; Beckmann MW; Ruebner M; Schoemaker MJ; Terry KL; El-Bahrawy MA; Coulson P; Etter JL; LaVigne-Mager K; Andress J; Grube M; Fischer A; Neudeck N; Robertson G; Farrell R; Barlow E; Quinn C; Hettiaratchi A; Casablanca Y; Erber R; Stewart CJR; Tan A; Yu Y; Boros J; Brand AH; Harnett PR; Kennedy CJ; Nevins N; Morgan T; Fasching PA; Vergote I; Swerdlow AJ; Candido Dos Reis FJ; Maxwell GL; Neuhausen SL; Barquin-Garcia A; Modugno F; Moysich KB; Crowe PJ; Hirasawa A; Heitz F; Karlan BY; Goode EL; Sinn P; Horlings HM; Høgdall E; Sundfeldt K; Kommoss S; Staebler A; Wu AH; Cohen PA; DeFazio A; Lee CH; Steed H; Le ND; Gayther SA; Lawrenson K; Pharoah PDP; Konecny G; Cook LS; Ramus SJ; Kelemen LE; Köbel M
Virchows Arch; 2022 Apr; 480(4):855-871. PubMed ID: 34782936
[TBL] [Abstract][Full Text] [Related]
20. Analysis of ovarian cancer cell secretome during epithelial to mesenchymal transition reveals a protein signature associated with advanced stages of ovarian tumors.
Lanfredi GP; Thomé CH; Ferreira GA; Silvestrini VC; Masson AP; Vargas AP; Grassi ML; Poersch A; Candido Dos Reis FJ; Faça VM
Biochim Biophys Acta Proteins Proteom; 2021 Jun; 1869(6):140623. PubMed ID: 33607274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]